These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 17052487)

  • 21. Psychotherapy in controlled psychopharmacology trials. Does it matter if we ignore it?
    Koek RJ; Hejran RN; Mintz J
    Contemp Clin Trials; 2005 Jun; 26(3):338-48. PubMed ID: 15911468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trial design issues: at least 10 things you should look for in clinical trials.
    Glasser SP; Howard G
    J Clin Pharmacol; 2006 Oct; 46(10):1106-15. PubMed ID: 16988199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Funding, disease area, and internal validity of hepatobiliary randomized clinical trials.
    Kjaergard LL; Gluud C
    Am J Gastroenterol; 2002 Nov; 97(11):2708-13. PubMed ID: 12425537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Placebo-controlled clinical trials in gastroenterology. A position paper of the American College of Gastroenterology.
    Sachar DB
    Am J Gastroenterol; 1984 Dec; 79(12):913-7. PubMed ID: 6507416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Placebos in clinical trials of peptic ulcer. ACG Committee on FDA-Related Matters.
    Smith JL
    Am J Gastroenterol; 1989 May; 84(5):469-74. PubMed ID: 2719003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors influencing the publication of randomized controlled trials in child health research.
    Hartling L; Craig WR; Russell K; Stevens K; Klassen TP
    Arch Pediatr Adolesc Med; 2004 Oct; 158(10):983-7. PubMed ID: 15466687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between funding source and study outcome in orthopaedic research.
    Leopold SS; Warme WJ; Fritz Braunlich E; Shott S
    Clin Orthop Relat Res; 2003 Oct; (415):293-301. PubMed ID: 14612659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of informed consent requirements on cardiac arrest research in the United States: exception from consent or from research?
    Nichol G; Huszti E; Rokosh J; Dumbrell A; McGowan J; Becker L
    Resuscitation; 2004 Jul; 62(1):3-23. PubMed ID: 15246579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and determinants of physician participation in conducting pharmaceutical-sponsored clinical trials and lectures.
    Ashar BH; Miller RG; Getz KJ; Powe NR
    J Gen Intern Med; 2004 Nov; 19(11):1140-5. PubMed ID: 15566444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Industry sponsorship and selection of comparators in randomized clinical trials.
    Lathyris DN; Patsopoulos NA; Salanti G; Ioannidis JP
    Eur J Clin Invest; 2010 Feb; 40(2):172-82. PubMed ID: 20050879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A survey identified publication bias in the secondary literature.
    Carter AO; Griffin GH; Carter TP
    J Clin Epidemiol; 2006 Mar; 59(3):241-5. PubMed ID: 16488354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reporting adverse events in randomized controlled trials.
    Nuovo J; Sather C
    Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):349-51. PubMed ID: 16998947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Placebo-free designs for evaluating new mental health treatments: the use of adaptive treatment strategies.
    Dawson R; Lavori PW
    Stat Med; 2004 Nov; 23(21):3249-62. PubMed ID: 15490427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethical framework for the use of sham procedures in clinical trials.
    Horng S; Miller FG
    Crit Care Med; 2003 Mar; 31(3 Suppl):S126-30. PubMed ID: 12626957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cross-sectional evidence-based review of pharmaceutical promotional marketing brochures and their underlying studies: is what they tell us important and true?
    Cardarelli R; Licciardone JC; Taylor LG
    BMC Fam Pract; 2006 Mar; 7():13. PubMed ID: 16515686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis?
    Brody BA; Dickey N; Ellenberg SS; Heaney RP; Levine RJ; O'Brien RL; Purtilo RB; Weijer C
    J Bone Miner Res; 2003 Jun; 18(6):1105-9. PubMed ID: 12817764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Trials: Design Flaws Associated with Use of a Placebo.
    Cleophas TJ
    Am J Ther; 1996 Jul; 3(7):529-534. PubMed ID: 11862286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The placebo mystique: Implications for clinical trial methodology.
    Clifford V
    J Paediatr Child Health; 2011 Jun; 47(6):361-6. PubMed ID: 21309878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II randomized, placebo-controlled trial of M. vaccae-derived protein (PVAC) for the treatment of psoriasis.
    Netto EM; Takahashi D; de Fátima Paim de Oliveira M; Barbosa P; Ferraz N; Paixão A; Oyafuso LK; Bortoletto C; Matos D; Paixão M; da Silva AO; Badaro R
    Vaccine; 2006 Jun; 24(23):5056-63. PubMed ID: 16621200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Placebo controls: scientific and ethical issues.
    Kowalski CJ
    Am J Bioeth; 2002; 2(2):33-4. PubMed ID: 12189073
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.